Evaluation of the Efficacy and Safety of Nifekalant Hydrochloride (NIF) Injection.

Evaluation of the Efficacy and Safety of Nifekalant Hydrochloride (NIF) Injection in the Treatment of Ventricular Tachycardia and Ventricular Fibrillation. A Multicenter, Randomized, Controlled, Open-label, Clinical Trial.

Efficacy and safety evaluation of amiodarone and Nifekalant hydrochloride(NIF) for the treatment of ventricular tachycardia and ventricular fibrillation.

After patients are hospitalized, they will be treated as usual in addition to antiarrhythmic drugs. DC will be performed again according to normal procedures for patients who were ineffective. Arrhythmia drugs can only be used with nifekalant or amiodarone at random.

Inclusion Criteria:

• Patients with persistent ventricular tachycardia or ventricular fibrillation who have a combined physical heart disease, or who have a conventional drug ineffective or persistent idiopathic ventricular tachycardia with amiodarone indications;
• Age ≥ 18 years old, gender is not limited.

Exclusion Criteria:

• Patients with prolonged ventricular tachycardia with QT interval and patients with QTc interval of more than 500 ms before administration;
• Patients with torsades de pointes (Tdp);
• Patients with Brugada syndrome;
• Patients with severe atrioventricular block and without pacing protection;
• Patients with hypertrophic cardiomyopathy (HCM) with ventricular septal thickness or (and) left ventricular wall ≥ 15 mm;
• Pregnant or lactating women;
• Patients who are not suitable for the study, considered by investigators.